United Therapeutics (UTHR) Gains from Sales and Divestitures (2018 - 2020)

United Therapeutics has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $104818.0 for Q1 2020.

• Gains from Sales and Divestitures for Q1 2020 came in at $104818.0, up 127.73% year-over-year; the trailing twelve-month figure through Mar 2020 was $104818.0 (up 127.73% YoY), and the FY2019 annual result was $74324.0, up 290.13% from the prior year.
• Gains from Sales and Divestitures came in at $104818.0 for Q1 2020 at United Therapeutics, up from $74324.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $104818.0 in Q1 2020 to a low of $17820.0 in Q2 2018.
• The 3-year median for Gains from Sales and Divestitures is $55192.0 (2019), against an average of $51762.5.
• Across the five-year window, Gains from Sales and Divestitures surged 290.13% in 2019 and jumped 127.73% in 2020, its largest moves.
• United Therapeutics' Gains from Sales and Divestitures stood at $19051.0 in 2018, then soared by 290.13% to $74324.0 in 2019, then soared by 41.03% to $104818.0 in 2020.
• The last three Gains from Sales and Divestitures figures came in at $104818.0 (Q1 2020), $74324.0 (Q4 2019), and $69761.0 (Q3 2019), per Business Quant data.